About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in New York | 22,668 Studies Near You | Clareo Health

Clinical Trials LocationsNew York

Clinical Trials in New York

Discover 22,668 clinical trials near New York, New York. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 561-580 of 22,668 trials

Active Not RecruitingNA< 1 mile

Clinical Study of Edwards Cardioband FIT Valve Repair System

NCT03382457

Clinical Study of the Edwards Cardioband FIT Repair System

Tricuspid Regurgitation

Edwards Lifesciences75 participantsStarted Jul 2018

Chicago, Illinois, United States • Rochester, Minnesota, United States • Morristown, New Jersey, United States +6 more locations

TERMINATEDPhase 1/2< 1 mile

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

NCT03382977

The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).

Glioblastoma Multiforme

VBI Vaccines Inc.70 participantsStarted Dec 2017

Irvine, California, United States • La Jolla, California, United States • Los Angeles, California, United States +9 more locations

Find Trials by Condition in New York

Breast Cancerin New York Lung Cancerin New York Prostate Cancerin New York Colorectal Cancerin New York Melanomain New York Leukemiain New York Lymphomain New York Pancreatic Cancerin New York Ovarian Cancerin New York Brain Cancerin New York Diabetes

Data from ClinicalTrials.govTerms

RECRUITINGPhase 4< 1 mile

Comparison of Outcomes of Management of Bowel Obstruction

NCT07084441

The Comparison of Outcomes of Management of Bowel Obstruction (COMBO) trial is a patient-level randomized trial of a short course of dexamethasone + supportive care vs supportive care alone for patients with adhesion-related small bowel obstruction (aSBO). The goal of the COMBO trial is to answer the question: Can Dexamethasone increases the proportion of patients with resolution of aSBO with non-operative management (without complication) based on an established minimal important clinical difference.

Adhesive Small Bowel Obstruction

University of Washington550 participantsStarted Feb 2026

New York, New York, United States • Seattle, Washington, United States • Seattle, Washington, United States +1 more locations

RECRUITING< 1 mile

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

NCT04688190

This multinational, investigator-initiated registry aims to investigate clinical outcomes of patients undergoing transcatheter mitral valve replacement (TMVR). The registry primarily focuses on patients treated with TMVR in real-world clinical practice. Patients evaluated for TMVR but not undergoing the procedure are no longer systematically included. Historical data may include such patients who subsequently underwent alternative treatments, including transcatheter edge-to-edge repair, mitral valve surgery, or medical/conservative therapy.

Mitral RegurgitationMitral Valve DiseaseMitral Annular Calcification

Universitätsklinikum Hamburg-Eppendorf1,000 participantsStarted Nov 2020

Tucson, Arizona, United States • Los Angeles, California, United States • Tampa, Florida, United States +40 more locations

Active Not RecruitingNA< 1 mile

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

NCT02701283

The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR. The purpose of the expanded use addendum to the Medtronic TAVR in Low Risk Patients Trial protocol is to conclude the randomized phase of the trial and initiate the single-arm, non-randomized, continued access phase of the trial.

Aortic Valve Stenosis

Medtronic Cardiovascular2,223 participantsStarted Mar 2016

Phoenix, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +84 more locations

RECRUITINGPhase 3< 1 mile

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT05879926

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

NRG Oncology3,960 participantsStarted Oct 2023

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +1235 more locations

COMPLETEDNA< 1 mile

ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

NCT01757665

The objective of this trial is to confirm that the modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.

Aortic StenosisMitral StenosisAortic Valve Insufficiency+2 more

Edwards Lifesciences777 participantsStarted Dec 2012

Birmingham, Alabama, United States • Los Angeles, California, United States • Sacramento, California, United States +29 more locations

RECRUITINGNA14 miles

Neurofeedback Intervention for Reading Deficits in Subacute Stroke

NCT04875936

The overall goal of this project is to advance a biologically-based approach to treatment of reading disorders after stroke, which will expand the limits of cognitive rehabilitation. Using a novel brain imaging technique, called real-time functional magnetic resonance imaging (fMRI) neurofeedback combined with right hand motor imagery, this project will re-instate brain activity in the left language-dominant hemisphere. Stroke patients will practice modulating their own brain activity using fMRI neurofeedback signal and will select the most effective mental strategies that help them maintain brain activation patterns associated with better reading recovery.

StrokeDyslexia, Acquired

Kessler Foundation28 participantsStarted Apr 2023

West Orange, New Jersey, United States

COMPLETEDPhase 319 miles

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

NCT04938830

This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).

Merck Sharp & Dohme LLC1,003 participantsStarted Nov 2021

Long Beach, California, United States • Orange, California, United States • Aurora, Colorado, United States +143 more locations

Active Not RecruitingPhase 280 miles

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

NCT06299098

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy. Parts A, B, and C of the study are looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Regeneron Pharmaceuticals1,005 participantsStarted Mar 2024

Anniston, Alabama, United States • Cullman, Alabama, United States • Phoenix, Arizona, United States +57 more locations

Active Not RecruitingPhase 380 miles

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600

The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.

Hypertension, Pulmonary

Actelion138 participantsStarted Jan 2020

Phoenix, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +113 more locations

Active Not RecruitingPhase 2/3116 miles

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20.

Head and Neck Squamous Cell Carcinoma (HNSCC)

Inhibrx Biosciences, Inc410 participantsStarted May 2024

Duarte, California, United States • Los Angeles, California, United States • Sacramento, California, United States +84 more locations

Active Not RecruitingNA190 miles

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

NCT04428944

The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF: 1. PV antral isolation alone (PVAI) 2. PV antral isolation plus ablation of drivers (PVAI+drivers) 3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies will employ contemporary catheter ablation technology using more efficient open irrigated tip cooling and contact force sensing.

Atrial Fibrillation

McGill University Health Centre/Research Institute of the McGill University Health Centre617 participantsStarted Jun 2021

Boston, Massachusetts, United States • Garran, Australian Capital Territory, Australia • Adelaide, Australia +29 more locations

TERMINATEDPhase 1/2190 miles

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

NCT06685068

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: * Part A: Dose escalation and dose level expansion * Part B: Tumor-specific expansion with dose optimization

Advanced Solid Tumor

Genmab23 participantsStarted Nov 2024

Boston, Massachusetts, United States • Grand Rapids, Michigan, United States • San Antonio, Texas, United States +1 more locations

RECRUITINGPhase 1190 miles

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT07300150

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).

Colorectal CancerPancreatic CancerNon-Small Cell Lung Cancer+1 more

PAQ Therapeutics, Inc.195 participantsStarted Nov 2025

Boston, Massachusetts, United States • San Antonio, Texas, United States • San Antonio, Texas, United States +2 more locations

RECRUITINGPhase 2/3203 miles

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Advanced Melanoma

Eikon Therapeutics740 participantsStarted May 2025

Chandler, Arizona, United States • Hot Springs, Arkansas, United States • Los Angeles, California, United States +104 more locations

RECRUITING251 miles

Functional Impact of Acute Respiratory Viral Infections in Older Adults

NCT07388173

The prevention of infectious diseases in older adults remains a major public health challenge, as acute respiratory infections are a leading cause of hospitalisation, mortality, and functional decline worldwide. Immunosenescence and environmental exposures increase susceptibility to infection and reduce vaccine effectiveness in this population. Respiratory viruses, including influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus, account for a substantial share of this burden, much of which is vaccine-preventable. However, their impact on functional decline and recovery in older adults remains insufficiently characterized. This international study aims to assess the effect of hospitalization for major respiratory viral infections on loss of autonomy in individuals aged 60 years and older, to inform targeted prevention and vaccination strategies.

Respiratory Infections in Old Age

University Hospital, Grenoble1,600 participantsStarted Jan 2026

Rochester, New York, United States • Amiens, France • Melun, France +21 more locations

TERMINATEDNA345 miles

Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness

NCT05694247

A Single Arm, Pivotal, Open Label, Multicenter Clinical Investigation to Evaluate the Clinical Safety and Performance of the CorNeat Keratoprosthesis, for Treatment of Corneal Blindness

Corneal DiseaseCorneal OpacityCorneal Injuries

CorNeat Vision Ltd.15 participantsStarted Jun 2024

Vancouver, British Columbia, Canada • Toronto, Ontario, Canada • Montpellier, France +3 more locations

RECRUITING1004 miles

Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis

NCT06354010

The purpose of this study is to characterize and assess the evolution of hearing impairment of patients with adulthood-onset bilateral sensorineural hearing loss carrying mutations on GJB2 gene.

Sensorineural Hearing Loss, Bilateral

Sensorion100 participantsStarted Jun 2024

Tampa, Florida, United States • Montpellier, France

TERMINATEDPhase 11581 miles

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

NCT06870487

The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid tumors that are advanced or metastatic (spread to other parts of the body). The study has three parts: * Part A will test PF-08046032 alone at increasing dose levels in participants with certain lymphomas (cancer that begins in cells of the immune system) and in participants with certain solid tumors whose disease has worsened on or after standard treatments. * Part B will test PF-08046032 (at selected doses) and sasanlimab in participants with certain solid tumors, including those whose disease has worsened on or after standard treatments as well as participants before receiving standard treatments. * Part C will further test the combination of PF-08046032 and sasanlimab in participants with specific types of solid tumors based on the results from Part A and Part B of the study. All participants will receive the study drug PF-08046032. Only participants in Part B and Part C of the study will also receive sasanlimab. PF-08046032 will be given as an intravenous (IV) infusion, which means it will be injected directly into a vein. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin.

Peripheral T Cell LymphomaDiffuse Large B-cell LymphomaClassical Hodgkin Lymphoma+3 more

Pfizer6 participantsStarted May 2025

San Antonio, Texas, United States • Seattle, Washington, United States • Seattle, Washington, United States +1 more locations

PreviousPage 29 of 1134Next

in New York

Heart Diseasein New York